Cellectis ADR (CLLS) Implied Volatility Current

Tracking CLLS implied volatility helps you identify when options premiums on Cellectis ADR are historically cheap or expensive, and where the best trades are hiding. Cellectis ADR implied volatility reflects the market's expectation of future price movement: when CLLS IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Cellectis ADR's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For CLLS, tracking metrics like CLLS IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on CLLS signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where CLLS implied volatility sits today versus where it has been. Our scanner ranks Cellectis ADR implied volatility against its historical range, surfaces extremes in CLLS IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Cellectis ADR IV is rich or cheap — measure it, then act on it.